Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months
- 5 November 2009
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 27 (47), 6589-6594
- https://doi.org/10.1016/j.vaccine.2009.08.032
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- FluBlok, a recombinant hemagglutinin influenza vaccineInfluenza and Other Respiratory Viruses, 2008
- The Underrecognized Burden of Influenza in Young ChildrenThe New England Journal of Medicine, 2006
- Dose‐Related Safety and Immunogenicity of a Trivalent Baculovirus‐Expressed Influenza‐Virus Hemagglutinin Vaccine in Elderly AdultsThe Journal of Infectious Diseases, 2006
- Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccineVaccine, 2006
- Influenza-Associated Deaths among Children in the United States, 2003–2004The New England Journal of Medicine, 2005
- Baculovirus as versatile vectors for protein expression in insect and mammalian cellsNature Biotechnology, 2005
- Production of a Recombinant Influenza Vaccine Using the Baculovirus Expression Vector SystemBioProcessing Journal, 2003
- Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young ChildrenThe New England Journal of Medicine, 2000
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenThe New England Journal of Medicine, 2000
- Recombinant Baculovirus Influenza A Hemagglutinin Vaccines Are Well Tolerated and Immunogenic in Healthy AdultsThe Journal of Infectious Diseases, 1996